✦ LIBER ✦

Comparison of Quantitative Immunofluorescence With Conventional Methods for HER2/neu Testing With Respect to Response to Trastuzumab Therapy in Metastatic Breast Cancer

✍ Scribed by Ross, J.S.; Slodkowska, E.A.; Boguniewicz, A.; Collea, R.

Book ID: 122011250
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 56 KB
Volume: 20
Category: Article
ISSN: 1043-321X
DOI: 10.1016/S1043-321X(09)79367-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Serum HER-2/neu and relative resistance

Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer

✍ Suhail M. Ali; Walter P. Carney; Francisco J. Esteva; Monica Fornier; Lyndsay Ha 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 175 KB 👁 2 views

Phosphorylated HER-2 tyrosine kinase and

Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC)

✍ Rosa Giuliani; Virginie Durbecq; Angelo Di Leo; Marianne Paesmans; Denis Larsimo 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 636 KB

KI67 and p53 are not predictive of tumor

KI67 and p53 are not predictive of tumor response or survival with trastuzumab-based therapy in metastatic breast cancer patients (pts) with her2/neu-overexpression

✍ A. Schneeweiss; F. Lenz; F. Beldermann; M. Geberth; R. Goerner; P. Sinn; H.-J. S 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 171 KB

5088 Analysis of factors predicting resp

5088 Analysis of factors predicting response to second-line trastuzumab- based therapy in patients (pts) with Her2-positive advanced breast cancer (ABC)

✍ R. Bartsch; C. DeVries; U. Pluschnig; P. Dubsky; S. Horvath; M. Rudas; R.M. Made 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 48 KB

Is the response duration to aromatase in

Is the response duration to aromatase inhibitor anastrozole in metastatic breast cancer correlated with Her-2/neu status? Preliminary results of a prospective, non-randomized study

✍ I Glogowska; R Sienkiewicz-Kozlowska; T Pienkowski; S Jaczewska; A Jagiello-Grus 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 172 KB

PCN69 COST-EFFECTIVENESS OF ADDING CAPEC

PCN69 COST-EFFECTIVENESS OF ADDING CAPECITABINE TO TRASTUZUMAB AND DOCETAXEL AS FIRST LINE THERAPY FOR PATIENTS WITH HER-2-POSITIVE METASTATIC BREAST CANCER (HER2+MBC)—RESULTS FROM SPAIN, FRANCE AND ITALY

✍ K Hieke; P Ducournau; F de Reydet de Vulpillières 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB